CD300LG/Nepmucin, His, Human

CD300LG/Nepmucin, His, Human

CD300LG is a novel O-glycosylated member of the CD300 antigen-like family. Besides a classical mucin-like domain, it contains a V-type Ig domain. CD300LG binds lymphocyte L-selectin via its Ig domain and supports lymphocyte rolling via its mucin-like domain. The unique structure and function of CD300LG suggest it may play an important role in inflammation.
Z04193
¥46,636.00

Ask us a question
Product Introduction
Species Human
Protein Construction
CD300LG/Nepmucin (Leu19-Arg247)
Accession # AAH25395		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 26.35 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background CD300LG is a novel O-glycosylated member of the CD300 antigen-like family. Besides a classical mucin-like domain, it contains a V-type Ig domain. CD300LG binds lymphocyte L-selectin via its Ig domain and supports lymphocyte rolling via its mucin-like domain. The unique structure and function of CD300LG suggest it may play an important role in inflammation.
Synonyms CD300LG; Nepmucin; CLM-9; TREM-4; CD300g; CLM9; TREM4

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.